STAT6 and neoplasm: One example is exoASO-STAT6, a precision drug candidate that uses EVs to selectively deliver antisense oligonucleotides to disrupt STAT6 signaling in tumor-associated macrophages (TAM) and induce antitumor immune responses [91].